ESMO 2018 | Not enough attention paid to bone health in prostate cancer

Skeletal immobility is identified as a significant problem in prostate cancer patients by Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, at the European Society for Medical Oncology (ESMO) 2018 Congress, held in Munich, Germany. Dr Crabb reflects on the data from a recent trial investigating the combination of abiraterone and radium-223 in prostate cancer patients, highlighting the vital need to pay more attention to bone health, and to determine how best patients should be assessed and monitored.